compound introduction
CCR2 antagonist 1 is a high-affinity and long-residence-time CCR2 antagonist, with a K i of 2.4 nM. In Vitro The combination of SAR and SKR in the hit-to-lead process results in the discovery of a new higheaffinity and longeresidenceetime CCR2 antagonist (CCR2 antagonist 1 (compound 15a), K i =2.4 nM; RT=714 min). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:CCR2 2.4 nM (Ki)
